FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 46 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the... September 10, 2021 FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma October 20, 2020 Combination Chemo Helps People with Leiomyosarcoma Live Longer October 2, 2024 Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL February 13, 2025 Load more HOT NEWS Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... Researchers Find New, Effective Tools to Determine Breast Cancer Risk Using... Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against...
